Ustekinumab beneficial through 1 year in SLE

Ustekinumab provides sustained clinical benefits through 1 year among patients with systemic lupus erythematosus, with a safety profile similar with its other indications, according to data published in Arthritis & Rheumatology.“Treatment options for SLE remain limited,” Ronald F. van Vollenhoven, MD, PhD, of Amsterdam University Medical Centers, told Healio Rheumatology.